Core Viewpoint - The inclusion of Guangzhou Taihe Cancer Hospital in the "Hong Kong-Macao Drug and Device Pass" list represents a significant breakthrough for the company in accessing international medical resources and enhancing its service capabilities in cancer treatment [1][2]. Group 1: Company Developments - The hospital has successfully passed the approval process to be listed as a designated medical institution under the "Hong Kong-Macao Drug and Device Pass" policy, which facilitates the introduction of innovative drugs and devices approved in Hong Kong and Macao but not yet available in mainland China [1]. - This policy is expected to broaden the legal supply channels for urgently needed clinical treatments, providing policy support for residents in the Greater Bay Area to access advanced medical services in line with international standards [1][2]. - The company has established professional barriers in precision treatment, proton therapy, and multidisciplinary diagnosis and treatment, which will be further strengthened by this new designation [1][3]. Group 2: Industry Implications - The advancement of the "Hong Kong-Macao Drug and Device Pass" not only enhances the service capabilities of individual institutions but also contributes to the construction of a high-level medical service network characterized by tiered diagnosis and regional collaboration [2]. - Designated medical institutions can attract patients from surrounding areas by introducing international innovative drugs and devices, gradually forming regional cancer treatment centers and optimizing the allocation of medical resources [2]. - The ongoing release of policy dividends in the Greater Bay Area is expected to accelerate the flow of cross-border medical resources, allowing the company to benefit continuously from its specialized and international strategic layout [2].